维奈托克治疗复发/难治急性髓系白血病的临床观察

严泽莹; 孙海敏; 陈钰

doi:10.7619/jcmp.20214194

维奈托克治疗复发/难治急性髓系白血病的临床观察

Clinical observation of venetoclax in treatment of relapsed or refractory acute myeloid leukemia

摘要

摘要:
目的观察维奈托克(venetoclax)联合低甲基化药物治疗复发/难治急性髓系白血病(AML)的疗效。
方法回顾性分析上海交通大学医学院附属瑞金医院北部院区血液科2020年1月—2021年8月收治的14例复发/难治AML患者的临床资料并进行随访。10例患者采用venetoclax联合阿扎胞苷治疗，另4例患者采用venetoclax联合地西他滨治疗。
结果疗效达完全缓解(CR)或形态学CR而血小板计数未完全恢复(CRi)共5例，部分缓解(PR) 3例，未缓解(NR) 6例。所有患者治疗后出现不同程度的骨髓抑制，发生肺部感染6例。
结论复发/难治AML患者预后差，venetoclax联合低甲基化药物治疗对部分患者效果显著，可达到CR, 且耐受性较好。

Abstract:
Objective To observe the efficacy of venetoclax combined with hypomethylated drugs in the treatment of relapsed or refractory acute myeloid leukemia (AML).
Methods Clinical materials of 14 patients with relapsed or refractory AML in the Department of Hematology of the Northern Branch of Ruijin Hospital Affiliated to the Medical College of Shanghai Jiaotong University from January 2020 to August 2021 were analyzed retrospectively and followed up. Ten patients were treated with venetoclax and azacytidine, and the other four patients were treated with venetoclax and decitabine.
Results There were 5 cases with curative effect of complete remission (CR) or morphological CR with incomplete recovery of platelet count (CRi), 3 cases with partial remission (PR) and 6 cases with no remission (NR). Bone marrow suppression occurred in all the patients after treatment, and pulmonary infection was observed in 6 cases.
Conclusion The prognosis of patients with relapsed or refractory AML is poor. Venetoclax combined with hypomethylated drugs has a significant effect in some patients, which can achieve the CR result, and has better tolerance.

HTML全文

参考文献(23)

施引文献

资源附件(0)